Clinical trials
Relapsed Large B-cell Lymphoma clinical trials
Below are recruiting relapsed large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 239 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06743503RecruitingPhase 1
UB-VV400 with rapamycin for relapsed or refractory B-cell cancers
This trial tests a new combination therapy (UB-VV400 plus rapamycin) for people with B-cell cancers that have come back or not responded to previous treatment. It aims to see if this approach is safe and effective.
NanjingAges 18 years+ - NCT06678282Recruiting
Testing an investigational cell therapy for B-cell lymphoma or leukemia
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
Zhenzhou, HenanAges 18–75 - NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+ - NCT06071871RecruitingPhase 2
A trial of 3 drugs before or after CAR-T for lymphoma
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
LondonAges 18 years+ - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT06521255RecruitingPhase 3
New drug combo vs standard for relapsed DLBCL
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
BeijingAges 18 years+ - NCT06570447RecruitingPhase 2
Glofitamab and chidamide for relapsed or refractory DLBCL
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07240194RecruitingPhase 2
A study of a new drug combo for large B-cell lymphoma with TP53 changes
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
Nanjing, JiangsuAges 18 years+ - NCT06919939RecruitingPhase 2
Epcoritamab and Loncastuximab for relapsed large B-cell lymphoma
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Miami, FloridaAges 18 years+ - NCT06689917Recruiting
JY231 injection for relapsed B-cell lymphoma or leukemia
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
Wuhan, HubeiAges 18–75 - NCT07044050RecruitingPhase 1
Study of OT-C001 natural killer cells for large B cell lymphoma
This trial tests a new treatment made from specially activated natural killer cells from a donor. It is for people with diffuse large B cell lymphoma that has come back or not responded to other treatments, including CAR T-cell therapy.
MontpellierAges 18 years+ - NCT07309900RecruitingPhase 1
Testing IASO208 for relapsed or hard-to-treat B-cell cancers
This trial tests a new treatment called IASO208 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if the drug can help shrink tumors and control the cancer.
Wuhan, HubeiAges 18–75 - NCT06996132RecruitingPhase 2
Combination treatment for aggressive B-cell lymphoma that has returned
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
TianjinAges 18–65 - NCT06931652RecruitingPhase 2
Epcoritamab with lenalidomide and rituximab for CNS lymphoma
This trial tests a new combination of drugs—epcoritamab, lenalidomide, and rituximab—for people with primary central nervous system lymphoma (PCNSL) that has come back or not responded to treatment. The goal is to see if this three-drug therapy can help control the cancer.
BordeauxAges 18 years+ - NCT06321289RecruitingPhase 1/Phase 2
Donor T cell therapy for B-cell lymphoma
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Beijing, Beijing MunicipalityAges 18–75 - NCT06532630RecruitingEarly Phase 1
CAR-T cell therapy for relapsed B-cell cancers
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
Hefei, AnhuiAges 14–70 - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06489808RecruitingPhase 2
Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07321301RecruitingPhase 2
CAR T-cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new type of CAR T-cell therapy for people with B-cell lymphoma or leukemia that has not responded to standard treatments. The therapy uses a special delivery system to help the cells target and kill cancer cells.
Beijing, Beijing MunicipalityAges 14–85 - NCT07240974RecruitingEarly Phase 1
Study of ZZSW-01 for B-cell blood cancers that returned or didn't respond
This trial tests a new drug called ZZSW-01 for people with certain B-cell blood cancers (like lymphoma or leukemia) that have come back or haven't gotten better after other treatments. It aims to see if the drug is safe and works against these cancers.
WuhanAges 18 years+ - NCT07259070RecruitingPhase 1/Phase 2
CAR T-cells targeting BAFF-R for resistant B-cell lymphoma
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07236203Recruiting
Study of CAR-T therapy for relapsed large B-cell lymphoma
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06116110Recruiting
Long-term follow-up after gene therapy treatment
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Gilbert, ArizonaAges 18 years+
Hear when a new Relapsed Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed large b-cell lymphoma?
- Yes. Clin2 currently lists 239 recruiting relapsed large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Relapsed or Refractory Large B-cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.